Data from an extension study of delgocitinib cream supports positive results from phase 3 trials for chronic hand eczema. The extension study showed continued efficacy and tolerability over 36 weeks, with no change in conclusions about its safety and efficacy. The DELTA 1 and DELTA 2 trials demonstrated that delgocitinib was effective in achieving clear or almost clear skin in patients with chronic hand eczema. The JAK inhibitor showed consistency in secondary endpoints such as the Hand Eczema Severity Index and a significant improvement in quality of life for patients. The need for effective therapies for chronic hand eczema is high, and delgocitinib cream could potentially address this unmet need.
Source link
Extension Data Reported for Chronic Hand Eczema Treatment
